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Abstract 
Background: Current treatments for hypercalcemia caused by lung cell carcinomas 
producing parathyroid hormone-related peptide (PTH-rp) have limited efficacy, probably 
because of their lack of effect on PTH-rp secretion. In this case study we explored the 
efficacy of the calcimimetic cinacalcet as suppressor of PTH-rp production.  
Patient: A 57-year-old male with severe and recurrent hypercalcemia induced by a PTH-rp-
producing squamous cell lung carcinoma, stage cT4N3M1b, poorly responding to standard 
treatments.  
Results: Serum PTH-rp levels were not affected by saline, calcitonin or zoledronate. PTH-rp 
decreased during chemotherapy and cinacalcet monotherapy. The combination of 
chemotherapy plus cinacalcet was most effective in rapidly reducing serum calcium and PTH-
rp.  
Conclusion: This case study is the first to suggest that cinacalcet may be of value in some 
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